share_log

UBS Downgrades Cano Health to Neutral, Lowers Price Target to $1.25

UBS Downgrades Cano Health to Neutral, Lowers Price Target to $1.25

瑞银将Cano Health的评级下调至中性,将目标价下调至1.25美元
Benzinga Real-time News ·  2023/01/06 07:57

UBS analyst Andrew Mok downgrades Cano Health (NYSE:CANO) from Buy to Neutral and lowers the price target from $12 to $1.25.

瑞银分析师安德鲁·莫克将Cano Health(纽约证券交易所代码:CANO)的评级从买入下调至中性,并将目标价从12美元下调至1.25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发